Brazil's HIV advocates predicted USAID funding cuts long before they happened, and their experience offers critical lessons for global health resilience. As the dissolution of USAID disrupts HIV programs worldwide, Brazil stands as a model of independence, yet faces ongoing challenges with pharmaceutical access and research funding.
How Brazil Achieved HIV Independence
Brazil's Unified Health System (SUS) provides free HIV prevention and treatment to all citizens, funded through constitutional mandates since 1988. This legal framework ensures that HIV programs are protected from foreign aid volatility, allowing Brazil to achieve milestones like eliminating HIV transmission to newborns in 2025.
Juliana Cesar, political liaison coordinator at the Brazilian HIV NGO Gestos, explained that civil society fought to include HIV care in the constitution. "It has been earmarked into our budgets. We have to make sure that we have enough money for that," she said during the Aids 2026 conference in Rio de Janeiro.
The Financial Transaction Tax Experiment
Brazil once implemented a Financial Transaction Tax to fund public health, but it was abolished in 2007. Cesar acknowledged the tax was flawed because it applied the same rate to all citizens regardless of income. Still, she encourages other countries to explore similar mechanisms for sustainable health financing.
Challenges Remain Despite Independence
Even with a robust public health system, Brazil faces limitations. Negotiations with pharmaceutical companies restrict access to the latest HIV preventions and treatments. Additionally, NIH funding cuts could curtail HIV research in Brazil, slowing innovation and progress.
Cesar noted that Brazil's unique position stems from healthcare being a constitutional right. This legal guarantee has enabled consistent funding, but it does not shield the country from global economic and political shifts.
Key Takeaways for Global HIV Advocacy
- Legal protection for health funding ensures stability against donor changes.
- Civil society engagement is vital for embedding HIV services in public systems.
- Progressive taxation can fund health, but must be equitable.
- Pharmaceutical negotiations remain a barrier for middle-income countries.
- Research funding needs diversification to avoid reliance on single donors.
Comparison: Brazil vs. USAID-Dependent Countries
| Aspect | Brazil | USAID-Dependent Countries |
|---|---|---|
| Health funding source | Constitutional budget | Foreign aid |
| HIV program stability | High | Vulnerable to cuts |
| Access to latest drugs | Limited by pharma | Often dependent on donor negotiations |
| Research capacity | At risk with NIH cuts | Minimal |
| Civil society role | Strong advocacy | Varies |
Lessons for Other Nations
Cesar has long urged countries to prioritize self-sufficiency in health financing. "We would see the trends," she said, referring to the predictable decline in donor support. Building resilient health systems requires political will, legal frameworks, and community involvement.
As the world watches USAID's dissolution, Brazil's example proves that independence is possible, but not without trade-offs. Countries must balance sustainability with innovation and equity.